Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022005871 - METHODS OF TREATING SARS-COV-2 INFECTION USING INHIBITORS OF LIPOGENESIS

Publication Number WO/2022/005871
Publication Date 06.01.2022
International Application No. PCT/US2021/038908
International Filing Date 24.06.2021
IPC
A61K 9/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
19lyophilised
A61K 9/51 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • NAAR, Anders Michael
Agents
  • BORDEN, Paula A.
Priority Data
63/045,50429.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING SARS-COV-2 INFECTION USING INHIBITORS OF LIPOGENESIS
(FR) MÉTHODES DE TRAITEMENT D'UNE INFECTION PAR LE SARS-COV-2 À L'AIDE D'INHIBITEURS DE LA LIPOGENÈSE
Abstract
(EN) The present disclosure provides methods of treating a SARS-CoV-2 infection in a patient infected with SARS-CoV-2. The present disclosure provides pharmaceutical compositions comprising an inhibitor of lipogenesis, optionally, in combination with an RdRp inhibitor and/or an anti-inflammatory agent.
(FR) La présente divulgation concerne des méthodes de traitement d'une infection par le SARS-CoV-2 chez un patient infecté par le SARS-CoV-2. La présente divulgation concerne des compositions pharmaceutiques comprenant un inhibiteur de lipogenèse, éventuellement, combiné à un inhibiteur de RdRp et/ou à un agent anti-inflammatoire.
Latest bibliographic data on file with the International Bureau